JPWO2019213174A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019213174A5 JPWO2019213174A5 JP2020560361A JP2020560361A JPWO2019213174A5 JP WO2019213174 A5 JPWO2019213174 A5 JP WO2019213174A5 JP 2020560361 A JP2020560361 A JP 2020560361A JP 2020560361 A JP2020560361 A JP 2020560361A JP WO2019213174 A5 JPWO2019213174 A5 JP WO2019213174A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- aryl
- heterocycloalkyl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000753 cycloalkyl group Chemical group 0.000 claims 57
- 125000003118 aryl group Chemical group 0.000 claims 53
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 53
- 125000001072 heteroaryl group Chemical group 0.000 claims 52
- 125000000217 alkyl group Chemical group 0.000 claims 48
- 150000003839 salts Chemical class 0.000 claims 36
- 239000012453 solvate Substances 0.000 claims 36
- 150000001875 compounds Chemical class 0.000 claims 34
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 26
- 229910052739 hydrogen Inorganic materials 0.000 claims 26
- 239000001257 hydrogen Substances 0.000 claims 26
- 229910052736 halogen Inorganic materials 0.000 claims 25
- 150000002367 halogens Chemical class 0.000 claims 25
- 150000002431 hydrogen Chemical class 0.000 claims 23
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 22
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 18
- 125000000304 alkynyl group Chemical group 0.000 claims 15
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 14
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 11
- 125000003342 alkenyl group Chemical group 0.000 claims 11
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000004404 heteroalkyl group Chemical group 0.000 claims 3
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims 2
- 150000001345 alkine derivatives Chemical class 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024078186A JP2024112864A (ja) | 2018-04-30 | 2024-05-13 | Ｃｄ７３阻害剤 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862664841P | 2018-04-30 | 2018-04-30 | |
| US62/664,841 | 2018-04-30 | ||
| US201862737647P | 2018-09-27 | 2018-09-27 | |
| US62/737,647 | 2018-09-27 | ||
| US201862757714P | 2018-11-08 | 2018-11-08 | |
| US62/757,714 | 2018-11-08 | ||
| US201862777697P | 2018-12-10 | 2018-12-10 | |
| US62/777,697 | 2018-12-10 | ||
| US201962810790P | 2019-02-26 | 2019-02-26 | |
| US62/810,790 | 2019-02-26 | ||
| PCT/US2019/030068 WO2019213174A1 (en) | 2018-04-30 | 2019-04-30 | Cd73 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024078186A Division JP2024112864A (ja) | 2018-04-30 | 2024-05-13 | Ｃｄ７３阻害剤 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021522280A JP2021522280A (ja) | 2021-08-30 |
| JPWO2019213174A5 true JPWO2019213174A5 (https=) | 2022-04-26 |
| JP2021522280A5 JP2021522280A5 (https=) | 2022-04-26 |
| JP7489323B2 JP7489323B2 (ja) | 2024-05-23 |
Family
ID=68386646
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560361A Active JP7489323B2 (ja) | 2018-04-30 | 2019-04-30 | Ｃｄ７３阻害剤 |
| JP2024078186A Pending JP2024112864A (ja) | 2018-04-30 | 2024-05-13 | Ｃｄ７３阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024078186A Pending JP2024112864A (ja) | 2018-04-30 | 2024-05-13 | Ｃｄ７３阻害剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US11325938B2 (https=) |
| EP (2) | EP3787635B1 (https=) |
| JP (2) | JP7489323B2 (https=) |
| KR (1) | KR20210018255A (https=) |
| CN (2) | CN112423764A (https=) |
| AU (1) | AU2019261976B2 (https=) |
| BR (1) | BR112020022068A2 (https=) |
| CA (1) | CA3098493A1 (https=) |
| IL (1) | IL304348B2 (https=) |
| MX (2) | MX2020011542A (https=) |
| SG (1) | SG11202010790XA (https=) |
| TW (1) | TW202014182A (https=) |
| WO (1) | WO2019213174A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018208980A1 (en) | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| US11377469B2 (en) | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| CN112423764A (zh) | 2018-04-30 | 2021-02-26 | 欧瑞克制药公司 | Cd73抑制剂 |
| EP3810109B1 (en) * | 2018-05-31 | 2024-08-07 | Peloton Therapeutics, Inc. | Compounds and compositions for inhibiting cd73 |
| AU2019288495B2 (en) | 2018-06-21 | 2024-02-08 | Antengene Therapeutics Limited | Ectonucleotidase inhibitors and methods of use thereof |
| AU2020256166A1 (en) | 2019-04-02 | 2021-10-14 | Aligos Therapeutics, Inc. | Compounds targeting PRMT5 |
| US12544391B2 (en) | 2019-07-16 | 2026-02-10 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| HUE072504T2 (hu) | 2019-10-30 | 2025-11-28 | Oric Pharmaceuticals Inc | CD73-inhibitorok |
| EP4251633A4 (en) * | 2020-11-25 | 2024-09-25 | Risen (Suzhou) Pharma Tech Co., Ltd. | CD73 INHIBITORS AND PHARMACEUTICAL USES THEREOF |
| WO2022237747A1 (zh) | 2021-05-11 | 2022-11-17 | 四川海思科制药有限公司 | 小分子cd73拮抗剂及其用途 |
| US20240140979A1 (en) * | 2022-10-03 | 2024-05-02 | Teon Therapeutics, Inc. | Heterocyclic inhibitors of cd73 for treatment of disease |
| WO2024076873A1 (en) * | 2022-10-03 | 2024-04-11 | Teon Therapeutics, Inc. | Heterocyclic inhibitors of cd73 for treatment of disease |
| CN116217644B (zh) * | 2023-04-24 | 2023-08-08 | 南京颐媛生物医学研究院有限公司 | 抗冠状病毒核糖核苷类化合物及其制备方法和应用 |
| WO2025162964A1 (en) | 2024-01-30 | 2025-08-07 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of endometriosis |
| WO2025233264A1 (en) | 2024-05-07 | 2025-11-13 | Innate Pharma | Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0477454A1 (en) * | 1990-09-28 | 1992-04-01 | Merrell Dow Pharmaceuticals Inc. | Novel phosphonate derivatives of certain nucleosides |
| WO2002048165A2 (en) | 2000-12-15 | 2002-06-20 | Pharmasset Ltd. | Antiviral agents for treatment of flaviviridae infections |
| US20040229839A1 (en) * | 2003-05-14 | 2004-11-18 | Biocryst Pharmaceuticals, Inc. | Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| WO2005020885A2 (en) | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| WO2007139946A2 (en) | 2006-05-25 | 2007-12-06 | University Of Tennessee Research Foundation | Gpcr ligands identified by computational modeling |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| WO2009127230A1 (en) | 2008-04-16 | 2009-10-22 | Curevac Gmbh | MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION |
| US20090274686A1 (en) * | 2008-05-02 | 2009-11-05 | Yat Sun Or | Nucleoside phosphonate derivatives |
| WO2015164573A1 (en) * | 2014-04-25 | 2015-10-29 | Vitae Pharmaceuticals, Inc. | Purine derivatives as cd73 inhibitors for the treatment of cancer |
| CN104530166B (zh) | 2014-12-04 | 2016-08-24 | 陕西汉江药业集团股份有限公司 | 选择性还原4,6-共轭双烯-3-酮甾体化合物的方法 |
| WO2017098421A1 (en) * | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
| HUE063388T2 (hu) * | 2016-01-08 | 2024-01-28 | Arcus Biosciences Inc | Ekto-5'-nukleotidáz modulátorok és ezek alkalmazása |
| TWI767937B (zh) * | 2016-09-09 | 2022-06-21 | 美商卡利泰拉生物科技公司 | 外核苷酸酶抑制劑及其使用方法 |
| CN110049767B (zh) * | 2016-10-03 | 2023-04-04 | 艾库斯生物科学有限公司 | 腺苷5′-核苷酸酶的抑制剂 |
| EP3541396A4 (en) | 2016-11-18 | 2020-07-22 | Arcus Biosciences, Inc. | CD73-MEDIATED IMMUNOSUPPRESSION INHIBITORS |
| JP7138351B2 (ja) | 2016-12-22 | 2022-09-16 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | エクトヌクレオチダーゼ阻害剤およびその使用方法 |
| US20200115404A1 (en) * | 2017-03-31 | 2020-04-16 | Peloton Therapeutics, Inc. | Cd73 inhibitors and uses thereof |
| WO2018208727A1 (en) | 2017-05-08 | 2018-11-15 | Eternity Bioscience Inc. | Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof |
| WO2018208980A1 (en) | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| US11377469B2 (en) | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| CN112423764A (zh) | 2018-04-30 | 2021-02-26 | 欧瑞克制药公司 | Cd73抑制剂 |
| EP3810109B1 (en) | 2018-05-31 | 2024-08-07 | Peloton Therapeutics, Inc. | Compounds and compositions for inhibiting cd73 |
| AU2019288495B2 (en) | 2018-06-21 | 2024-02-08 | Antengene Therapeutics Limited | Ectonucleotidase inhibitors and methods of use thereof |
| EP3843714B1 (en) | 2018-08-27 | 2025-11-12 | Arcus Biosciences, Inc. | Cd73 inhibitors |
| KR20220024629A (ko) | 2019-06-20 | 2022-03-03 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 엑토뉴클레오티다제 억제제 및 이의 사용 방법 |
| US12544391B2 (en) | 2019-07-16 | 2026-02-10 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| HUE072504T2 (hu) | 2019-10-30 | 2025-11-28 | Oric Pharmaceuticals Inc | CD73-inhibitorok |
-
2019
- 2019-04-30 CN CN201980044455.4A patent/CN112423764A/zh active Pending
- 2019-04-30 BR BR112020022068-0A patent/BR112020022068A2/pt not_active Application Discontinuation
- 2019-04-30 EP EP19796584.1A patent/EP3787635B1/en active Active
- 2019-04-30 CN CN202510454173.9A patent/CN120699076A/zh active Pending
- 2019-04-30 TW TW108115143A patent/TW202014182A/zh unknown
- 2019-04-30 EP EP25202200.9A patent/EP4674481A3/en active Pending
- 2019-04-30 MX MX2020011542A patent/MX2020011542A/es unknown
- 2019-04-30 KR KR1020207034512A patent/KR20210018255A/ko not_active Ceased
- 2019-04-30 AU AU2019261976A patent/AU2019261976B2/en active Active
- 2019-04-30 IL IL304348A patent/IL304348B2/en unknown
- 2019-04-30 CA CA3098493A patent/CA3098493A1/en active Pending
- 2019-04-30 SG SG11202010790XA patent/SG11202010790XA/en unknown
- 2019-04-30 JP JP2020560361A patent/JP7489323B2/ja active Active
- 2019-04-30 WO PCT/US2019/030068 patent/WO2019213174A1/en not_active Ceased
-
2020
- 2020-10-23 US US17/078,567 patent/US11325938B2/en active Active
- 2020-10-29 MX MX2023002507A patent/MX2023002507A/es unknown
-
2022
- 2022-03-17 US US17/697,318 patent/US11807658B2/en active Active
-
2023
- 2023-09-28 US US18/476,763 patent/US20240124512A1/en not_active Abandoned
-
2024
- 2024-05-13 JP JP2024078186A patent/JP2024112864A/ja active Pending
-
2025
- 2025-06-11 US US19/234,635 patent/US20250368677A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019213174A5 (https=) | ||
| JP2021522280A5 (https=) | ||
| JP2024100974A5 (https=) | ||
| JP2020529994A5 (https=) | ||
| JP2017512833A5 (https=) | ||
| JP2020504707A5 (https=) | ||
| JP2021120411A5 (https=) | ||
| RU2019116512A (ru) | Ингибиторы magl | |
| JP2018531218A5 (https=) | ||
| JP2019531279A5 (https=) | ||
| JP2018504437A5 (https=) | ||
| JP2015537008A5 (https=) | ||
| JP2017504576A5 (https=) | ||
| JPWO2022222921A5 (https=) | ||
| JP2019524883A5 (https=) | ||
| JP2017536395A5 (https=) | ||
| JP2016531121A5 (https=) | ||
| RU2015141278A (ru) | Новое производное 3-(4-(бензилокси)фенил)гекс-4-иновой кислоты, способ его получения и фармацевтическая композиция для профилактики и лечения метаболического заболевания, включающая его в качестве эффективного ингредиента | |
| CN109790145A (zh) | 二氢嘧啶类化合物及其制备方法和用途 | |
| JP2020511536A5 (https=) | ||
| JPWO2020252589A5 (https=) | ||
| JPWO2019241292A5 (https=) | ||
| RU2019128063A (ru) | Углеводородсульфонилзамещенные пиридины и их применение при лечении рака | |
| JPWO2019165358A5 (https=) | ||
| JPWO2019222266A5 (https=) |